Panobinostat (LBH589)

目录号：S1030 别名： NVP-LBH589

Molecular Weight(MW): 349.43

Panobinostat (LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Phase 3。

规格

价格

库存

购买数量

10mg	RMB 731.86	现货
50mg	RMB 2189.52	现货
200mg	RMB 5485.18	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献122篇：

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 159(5):1110-25

PubMed: 25416949 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):185

PubMed: 31053152 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1666-1676

PubMed: 30954557 ( click the link to review the publication )

Biomolecules, 2019, 9(5)

PubMed: 31083537 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(2)

PubMed: 30455231 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )
Mol Carcinog, 2019, 58(2):234-246

PubMed: 30303565 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

Childs Nerv Syst, 2019, 35(5):823-831

PubMed: 30815722 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Cancer Lett, 2018, 417:152-160

PubMed: 29306016 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1705-1716

PubMed: 29748211 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(2):201-212

PubMed: 29260509 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

Arch Toxicol, 2017, 91(1):365-391

PubMed: 27015953 ( click the link to review the publication )

Arch Toxicol, 2017, 91(2):839-864

PubMed: 27188386 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Int J Nanomedicine, 2017, 12:1385-1399

PubMed: 28260886 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Exp Cell Res, 2017, 350(1):218-225

PubMed: 27914787 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169485

PubMed: 28052119 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )
Blood Adv, 2017, 1(19):1575-1583

PubMed: 29296798 ( click the link to review the publication )

Genom Data, 2017, 12:14-16

PubMed: 28239551 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:127-148

PubMed: 27761818 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

Retrovirology, 2016, 13(1):36

PubMed: 27206407 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Am J Transl Res, 2016, 8(9):3893-3902

PubMed: 27725868 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )

Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Biomaterials, 2015, 73:110-9

PubMed: 26406451 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Arch Toxicol, 2015, 89(9):1599-618

PubMed: 26272509 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

Mol Pharm, 2015, 12(7):2469-76

PubMed: 26030093 ( click the link to review the publication )
Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

Exp Hematol, 2015, 43(6):448-61

PubMed: 25704054 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )

Br J Cancer, 2014, 111(2):281-91

PubMed: 24946002 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

Mol Carcinog, 2014, 53(9):722-35

PubMed: 23475695 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )

PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )
Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1325-34

PubMed: 23515752 ( click the link to review the publication )

PLoS One, 2013, 8(8):e74253

PubMed: 23991216 ( click the link to review the publication )

PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )

Genet Mol Res, 2013, 12(4):5405-13

PubMed: 24301913 ( click the link to review the publication )

The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

J Neurooncol, 2012, 110(3):335-48

PubMed: 23054560 ( click the link to review the publication )

Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )
Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

Panobinostat (LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Phase 3。

靶点

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

体外研究

LBH589诱导MOLT-4和Reh细胞凋亡，这种作用具有时间和剂量依赖性。而且，LBH589作用于MOLT-4细胞比作用于Reh细胞更有效。LBH589明显阻止MOLT-4 和Reh细胞的生长，处理48小时，具有剂量依赖性。与对照组细胞相比，用LBH589处理的细胞，在细胞周期的G2/M期的细胞数量增多2到3倍。LBH589与组蛋白H3K9和H4K8的乙酰化作用相关，LBH589也降低c-Myc的表达水平，具有剂量依赖性。LBH589也增强p21的表达水平。最低剂量的LBH589（10 nM）处理Reh细胞，最初增强c-Myc的表达水平，之后一直降低c-Myc的表达水平。此外，LBH589促进mRNA水平的促凋亡和DNA修复基因的大量增多。在GADD45G启动子作用下，LBH589诱导乙酰化的组蛋白H3 和H4水平的增多。^[1]此外, LBH589抑制非小细胞肺癌细胞系生长，如人类H1299,L55和A549，IC50分别为5,11和30 nM；间皮瘤细胞生长，如人类OK-6和 Ok-5，IC50分别为5和7 nM；及小细胞肺癌细胞系生长，如人类RG-1和LD-T，IC50分别为4和5 nM。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	NHHEO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUiwMVExKM7:TR?=	MV[wMVQh\A>?		NVXLdGdFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NG\tZVMzPjdyMke4OC=>
HepG2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1v5VFAuOTBizszN	NYXXWo5POC12IHS=		NXGzPWpJcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NXfkOI9TOjZ5MEK3PFQ>
HT29	NXrifnVkTnWwY4Tpc44hSXO\|YYm=	NUTUVGVVPTEEoH7N	NHTBfnEzPC15MjDo		MknobY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkA1QMLiaNMg	NIHYZVkzPjdyMke4OC=>
HepG2	M4izO2Z2dmO2aX;uJGF{e2G7	MnTYOVDDqG6P	MWeyOE04OiCq		NE[xeVhqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB\|IHHmeIVzKDJ2wrDoxsA>	MnLQNlY4ODJ5OES=
HCC827	M4nNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVW1M\|cvPS9zMDDuUS=>	M1XSdlczyqCq	NWLOeGZqTE2VTx?=	MYXlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>?	NIHKU3UzPjZ5NUS4OC=>
A549	NUPsXYZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\ZNVAwOTVxMkCgcm0>	MoTzO\|LDqGh?	MlzaSG1UVw>?	NGPlfXNmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?=	Mn3qNlY3PzV2OES=
NCI-H460	M1ixWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3qwbFExNzJyL{OwJI5O	NGDLXYw4OsLiaB?=	MX;EUXNQ	NUi1UWhO\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	NVT1XIZ6OjZ4N{W0PFQ>
J89GFP	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml;KSG1UV8Li	MX3FR\|UxRTR7Lki1JOKyKDF{Lk[1JI5O	NGK4d2czPjV4M{W2PC=>
THP89GFP	M4fqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mof2SG1UV8Li	NEf0d25GSzVyPUG5MlM1KMLzIE[uOFMhdk1?	MVyyOlU3OzV4OB?=
SK-NEP-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFz0[3gxNjBz4pETNVAvOCEQvF2=	MlTLNlQhcA>?	MnG0SG1UV8Li	NXjENG5SUUN3ME23Ok4{PCCwTR?=	NYHVWVJ4OjZzN{[yNVk>
G401	NGDZW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MViwMlAy6oDVMUCuNEDPxE1?	MX:yOEBp	MYjEUXNQyqB?	NHKycohKSzVyPUG0N{4xOiCwTR?=	MljDNlYyPzZ{MUm=
SK-NEP-1	NGn2fXFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NHzxfZc2OCCwTR?=	MUOx5qCUPCCm	NX7iO3JkTE2VT9Mg	NIW0VoJz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ?	Mor4NlYyPzZ{MUm=
G401	M{H5U2NmdGxiVnnhZoltcXS7IFHzd4F6	MWi1NEBvVQ>?	MmPKNgKBmzRiZB?=	NVrnZnNVTE2VT9Mg	Ml64doVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz	NFTXSpozPjF5NkKxPS=>
SK-NEP-1	MX7BdI9xfG:\|aYOgRZN{[Xl?	M325fFUxNzFyMDDuUS=>	MmD4NlQhcA>?	MXrEUXNQyqB?	MWLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MWSyOlE4PjJzOR?=
G401	NYHMXW1HSXCxcITvd4l{KEG\|c3H5	NYfqfXZtPTBxMUCwJI5O	NUnCV5ZnOjRiaB?=	M3fIPWROW00EoB?=	NFfZXGNqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	Ml;WNlYyPzZ{MUm=
SK-NEP-1	NUTUZWZrTnWwY4Tpc44hSXO\|YYm=	MYK1NE8yODBibl2=	NVzWR4M4OjRiaB?=	NFzOcldFVVORwrC=	M1LyO5Npd3e\|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25?	MkSzNlYyPzZ{MUm=
G401	MUHGeY5kfGmxbjDBd5NigQ>?	NUfkUGs6PTBxMUCwJI5O	NWTySYpiOjRiaB?=	Mn\qSG1UV8Li	M3zDWpNpd3e\|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25?	MV2yOlE4PjJzOR?=
SK-NEP-1	MUfGeY5kfGmxbjDBd5NigQ>?	Moq3OVAwOTByIH7N	NV3MepV7OjRiaB?=	MmDQSG1UV8Li	M{nCbIlv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh	MYCyOlE4PjJzOR?=
G401	NX;HXYMzTnWwY4Tpc44hSXO\|YYm=	NHrXSJo2OC9zMECgcm0>	Ml;2NlQhcA>?	MXrEUXNQyqB?	NXG1NY9ZcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB?	MUSyOlE4PjJzOR?=
RPMI 8226	MWLD[YxtKFO3co\peoFtKEG\|c3H5	NITNUJczNzRxNjDuUS=>	NHTpTpk1QOLCiXi=		NHGzfpFqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq	MkXpNlYxODB{OUK=
OPM2	NFq4emhE\WyuIGP1dpZqfmGuIFHzd4F6	NF74NGozNzRxNjDuUS=>	NV;DWG9XPDkkgJno		M1izWIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh?	MYOyOlAxODJ7Mh?=
U266	NGTJTHNE\WyuIGP1dpZqfmGuIFHzd4F6	NGDKPW0zNzRxNjDuUS=>	MWe0PQKBkWh?		M3zL[olv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh?	MXyyOlAxODJ7Mh?=
H929	MljDR4VtdCCVdYL2bZZidCCDc4PhfS=>	NID1UmgzNzRxNjDuUS=>	NXHjcllWPDkkgJno		NW\zfJVscW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	MVmyOlAxODJ7Mh?=
RPMI 8226	NHPCXmpCeG:ydH;zbZMhSXO\|YYm=	M2TLd\|TjiImwTR?=	NYjmcot[OjRxNEigbC=>		NVrEZYR4cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	NHjKWVczPjByMEK5Ni=>
HCC827	NGLCOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHhengyOCCwTR?=	NYnoT2FiPDhiaB?=	NHy1XFRFVVOR	NF20ZlRmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?=	M{DSZVI2QTR2NkG3
NCI-H23	NVX4dopCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIS3V4wyOCCwTR?=	M2DQSFQ5KGh?	NIq1UIZFVVOR	M3n1SYVvcGGwY3XzJINqe3CuYYTpckB{\W6\|aYTpeol1gcLi	NYfNU4xqOjV7NES2NVc>
AML3	NGnwNYlHfW6ldHnvckBCe3OjeR?=	NIjnSYcxNTFizszN	NWXRcm1zOjUEoHi=		M3;ybYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M4PaelI2PjF{OUSx
ML-1	NXLxWVJQTnWwY4Tpc44hSXO\|YYm=	MVOwMVEh\|ryP	NEHaZ4MzPMLiaB?=		M{jJXYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NVWzUnY6OjV4MUK5OFE>
RPMI-8226vr10	MVnGeY5kfGmxbjDBd5NigQ>?	MmrVNE0yKM7:TR?=	M{DBbVI1yqCq		NFrVNGVqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NHTKNFMzPTZzMkm0NS=>
ML-1	MYfGeY5kfGmxbjDBd5NigQ>?	NGjZR\|QyKM7:TR?=	M4fiSlI1yqCq		M4n4Tolv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhPC2ob3zk	NHHoXIkzPTZzMkm0NS=>
RPMI-8226vr10	NYXWd\|FYTnWwY4Tpc44hSXO\|YYm=	NEK0R4QyKM7:TR?=	NGX3PI4zPMLiaB?=		M2K5Xolv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhOi53LX\vcIQ>	MXKyOVYyOjl2MR?=
SK-N-BE (2)	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYLHflUxOjUkgJno		MnHLTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P	Mk\YNlU{ODh7MU[=
SK-N-BE (2), PAN MK	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFzPWJIzPOLCiXi=		NX\6WIpMUUN3ME2xNFQvOOLCidMx5qCKPy56IH7N	NY\ZNGlCOjV\|MEi5NVY>
SK-N-BE (2), MK PAN	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFTESGMzPOLCiXi=		M4XTO2lEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2=	Mnj0NlU{ODh7MU[=
SK-N-AS	M{DIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXOyOQKBkWh?		M{HJfmlEPTB;M{euNgKBkcLz4pEJNk41KG6P	NV64WZBmOjV\|MEi5NVY>
SK-N-DZ	M1PoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIrJcZMzPOLCiXi=		MnzZTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1?	MoXpNlU{ODh7MU[=
Caki-1	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPzdHV5OTBxMkWvOVAhdk1?	NInKdJI1QCCq		NED4e3pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	MmHFNlUzPzlzOUG=
ACHN	MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXixNE8zPS93MDDuUS=>	M3HGO\|Q5KGh?		MnvBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{	NUHzemdwOjV{N{mxPVE>
769-P	M4TJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWKxNE8zPS93MDDuUS=>	MVO0PEBp		NHz1bIhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	MVGyOVI4QTF7MR?=
786-O	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrTNVAwOjVxNUCgcm0>	NIXze2I1QCCq		NU\rWnBGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny	MVyyOVI4QTF7MR?=
Caki-1	M3K0bGFxd3C2b4Ppd{BCe3OjeR?=	M2DXfVUxKG6P	MYm0PEBp		NGXk[nNqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	MXWyOVI4QTF7MR?=
ACHN	MkHXRZBweHSxc3nzJGF{e2G7	Mo\YOVAhdk1?	MYW0PEBp		NXXRT5RPcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK=	MWeyOVI4QTF7MR?=
769-P	NF7nXHlCeG:ydH;zbZMhSXO\|YYm=	MlvuOVAhdk1?	MVi0PEBp		NEDpeJZqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	MVyyOVI4QTF7MR?=
786-O	MmfqRZBweHSxc3nzJGF{e2G7	Mnq0OVAhdk1?	NH3HeXM1QCCq		MXjpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>?	Mk\KNlUzPzlzOUG=
Caki-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vnWVI2NzVyIH7N	MXW0PEBp	Mlq0SG1UVw>?	NYrMcmVGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=>	MV[yOVE4PjN3NB?=
ACHN	M1[1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHuc\|JEOjVxNUCgcm0>	NGfnXpI1QCCq	M4C3OGROW09?	MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk	M2LjbVI2OTd4M{W0
769-P	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37IXVI2NzVyIH7N	NEnK[FE1QCCq	MnXjSG1UVw>?	NXOxfo45cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=>	NH\hb4QzPTF5NkO1OC=>
Caki-1	M3HlfGNwdG:weTDGc5Ju[XSrb36gRZN{[Xl?	MV[1NEBvVQ>?	NXLhfFNuPy1zNDDk	MVjEUXNQ	M1ThV5N2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh	NX;YS3RkOjVzN{[zOVQ>
ACHN	M3u4cGNwdG:weTDGc5Ju[XSrb36gRZN{[Xl?	NXzzWmtnPTBibl2=	NHzFfWM4NTF2IHS=	MlO0SG1UVw>?	MmS0d5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA>	NFnLSYwzPTF5NkO1OC=>
769-P	M{O3SWNwdG:weTDGc5Ju[XSrb36gRZN{[Xl?	M1LGSVUxKG6P	MkW2O{0yPCCm	MVLEUXNQ	NWHiO3dQe3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB?	NXvpNI9JOjVzN{[zOVQ>
Caki-1	M1mwXmFxd3C2b4Ppd{BCe3OjeR?=	NHLB[pk2OCCwTR?=	NF\KZ4Q1QCCq	M2rRTmROW09?	NFvzNnFqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NHO4O\|EzPTF5NkO1OC=>
ACHN	NV3IcGN3SXCxcITvd4l{KEG\|c3H5	NEnYeI02OCCwTR?=	MXS0PEBp	NXK1[\|JjTE2VTx?=	MXLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NYXQelB[OjVzN{[zOVQ>
769-P	MVHBdI9xfG:\|aYOgRZN{[Xl?	NXrZeGlbPTBibl2=	MUC0PEBp	NXvQemZrTE2VTx?=	MXnpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NUDVeG1xOjVzN{[zOVQ>
MDA-MB-231	MWjNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk>	NUK0fXF7OTEEoH7N	NFrsNlg{yqCm	NYHTRVhpTE2VTx?=	MX7hcJRmenNiY3XscEBud3KyaH;sc4d6yqB?	NVnhU\|VROjR6MUC0PVc>
BT-549	MV7Nc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk>	MXWxNOKhdk1?	M{Dhb\|PDqGR?	MXrEUXNQ	MYXhcJRmenNiY3XscEBud3KyaH;sc4d6yqB?	M4m2RlI1QDFyNEm3
MCF-7	MoLjUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6	MV:xNOKhdk1?	Mnq4N:Kh\A>?	M1rqXGROW09?	MnHPZYx1\XK\|IHPlcIwhdW:{cHjvcI9ogcLi	NHjJ[5gzPDhzMES5Oy=>
MCF-7	MUnGeY5kfGmxbjDBd5NigQ>?	MmX6OU02OCCwTR?=	Ml[zNlQhcA>?	NWPjRm9uTE2VTx?=	NVO1SoNIemWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>?	M4XJ[FI1OzZ4NEC3
CTS	NWS5dlh4SXCxcITvd4l{KEG\|c3H5	M4XYPFDjiJN2MDDuUeKh	NIXUfmI1QCCq		NXzLTZJmcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NUjIWYpJOjR{NES0Nlk>
OCI-AML3	MmXyRZBweHSxc3nzJGF{e2G7	M1HmOVDjiJN2MDDuUeKh	NWT0SYF7PDhiaB?=		M37tUIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NVHZUYs6OjR{NES0Nlk>
U937	NUXybFRESXCxcITvd4l{KEG\|c3H5	Mo\nNQKBmzRyIH7NxsA>	Mm[yOFghcA>?		M4DUbIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFLWUFczPDJ2NESyPS=>
PC3	M{T4ZWFxd3C2b4Ppd{BCe3OjeR?=	MXKwMVExOCCwTR?=	M3Pm[FI1NzR6IHi=		MVXpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M{PzW\|I1OTZ\|MkOw
PC3-AR	MVfBdI9xfG:\|aYOgRZN{[Xl?	MkfGNE0yODBibl2=	NGfaeZUzPC92ODDo		NULr[\|dLcW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NHTHe5EzPDF4M{KzNC=>
PC3	M2nhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfZTI1nOC1zMECgcm0>	NH3Y[5gzPC92ODDo		MWnpcoR2[2W\|IHHjZ5VufWyjdHnvckBw\iC\|dXLHNUBxd3C3bHH0bY9v	Mki3NlQyPjN{M{C=
PC3-AR	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPxNHk5OC1zMECgcm0>	M371RVI1NzR6IHi=		MWnpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJJRp\SCJMl2gdIhie2V?	NFTwV40zPDF4M{KzNC=>
PC3	NGDPS5pHfW6ldHnvckBCe3OjeR?=	NXfiTmx2OC1zMECgcm0>	M4O3d\|I1KGh?		NY[2XZM1e3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4>	MYqyOFE3OzJ\|MB?=
PC3-AR	Mk\xSpVv[3Srb36gRZN{[Xl?	NH;GUZoxNTFyMDDuUS=>	NG\LXmYzPCCq		MkW1d5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6=	M{XSblI1OTZ\|MkOw
OS-RC-2	MoXSR4VtdCCYaXHibYxqfHliQYPzZZk>	Mny3NE0yODByIH7N	NHrZXpUzPC92OD:3NkBp	M4ntcGROW09?	Mn7S[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MXSyOFE1PDd\|Nx?=
OS-RC-2	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HudlUxKG6P	NW\D[lVFPDhiaB?=	NYC3XWZkTE2VTx?=	NIHsXGtqdmS3Y3XzJGczN01iYYLy[ZN1	MkfONlQyPDR5M{e=
OS-RC-2	MUnBdI9xfG:\|aYOgRZN{[Xl?	MUm1NEBvVQ>?	MnLiOFghcA>?	NWnSfnlFTE2VTx?=	MYjpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MXmyOFE1PDd\|Nx?=
SK-N-AS	MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX2w5qCUQDBibl2=	MVW0PEBp		M{HmbWlEPTB;MkeuOEBvVQ>?	NHviZpczPDB7OEe5PS=>
SK-N-DZ	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXsNQKBmzhyIH7N	M2Ozd\|Q5KGh?		M4nrWWlEPTB;MkGuPUBvVQ>?	M{nSd\|I1ODl6N{m5
SK-N-SH	Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETpV2wx6oDVOECgcm0>	M363bVQ5KGh?		NGPzTpZKSzVyPUeyMlMhdk1?	NXLHcHQ3OjRyOUi3PVk>
SK-N-BE	NH[wUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWew5qCUQDBibl2=	MWm0PEBp		MWTJR\|UxRTd3LkSgcm0>	MYKyOFA6QDd7OR?=
SK-N-AS	NUPwUm9ySXCxcITvd4l{KEG\|c3H5	M4\rR\|DjiJN6MDDuUS=>	M{nMU\|Q5KGh?		MmjqdI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	NXrLT2hbOjRyOUi3PVk>
SK-N-DZ	MXzBdI9xfG:\|aYOgRZN{[Xl?	MX2w5qCUQDBibl2=	NUH4WnhPPDhiaB?=		NVfvTmFOeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v	NHK0[5ozPDB7OEe5PS=>
SK-N-SH	MnS0RZBweHSxc3nzJGF{e2G7	NG[5NoMx6oDVNECgcm0>	NELmeFY1QCCq		NILP[VBxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44>	NGnXfnIzPDB7OEe5PS=>
SK-N-BE	M4DiWWFxd3C2b4Ppd{BCe3OjeR?=	NFPrbYsx6oDVNECgcm0>	MVW0PEBp		M1;MW5BwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	M1\GeFI1ODl6N{m5
SK-N-AS	MX;GeY5kfGmxbjDBd5NigQ>?	NHL0N5Qx6oDVOECgcm0>	MlyzOFghcA>?		MlLxbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=>	M4LtfFI1ODl6N{m5
SK-N-DZ	MYjGeY5kfGmxbjDBd5NigQ>?	M{S5WlDjiJN6MDDuUS=>	MlfTOFghcA>?		NGfEdWRqdmS3Y3XzJIEh\G:\|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[UA{KGGwZDDQRXJR	NUTy[opROjRyOUi3PVk>
SK-N-SH	M1vISGZ2dmO2aX;uJGF{e2G7	M1G1SVDjiJN2MDDuUS=>	NXHMU5NRPDhiaB?=		NWfh[o82cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>?	NFXiWI0zPDB7OEe5PS=>
SK-N-BE	NWD6U5JMTnWwY4Tpc44hSXO\|YYm=	MonnNQKBmzRyIH7N	NIDOTYk1QCCq		M4DUcolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA>	MofoNlQxQTh5OUm=
HCC-LM3	M17ubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVixMVExODBibl2=	M1\TUFI1NzR6L{eyJIg>	MkDnSG1UVw>?	NUHpNpVycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NYOxO\|ZIOjRyOUO5OVY>
HepG2	NHS0O3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfiNU0yODByIH7N	NELOOY8zPC92OD:3NkBp	MUXEUXNQ	MnXjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NFfyOo4zPDB7M{m1Oi=>
SMMC-7721	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnKNU0yODByIH7N	MVyyOE81QC95MjDo	MmDRSG1UVw>?	MnnTbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MnPmNlQxQTN7NU[=
HCC-LM3	NVHFdpZoSXCxcITvd4l{KEG\|c3H5	M3vOdFUxKG6P	MlXiOFghcA>?	MXzEUXNQ	NUXmb5BMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG\|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl?	NWTEW\|F6OjRyOUO5OVY>
HepG2	NVKyW4ZbSXCxcITvd4l{KEG\|c3H5	M33j[\|UxKG6P	MV:0PEBp	MUfEUXNQ	MnTobY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk>	MVWyOFA6Ozl3Nh?=
SMMC-7721	NFTrO3RCeG:ydH;zbZMhSXO\|YYm=	MWq1NEBvVQ>?	NUi4[YVYPDhiaB?=	M4\Je2ROW09?	M3PrS4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6	M{P4bVI1ODl\|OUW2
HCC-LM3	M1nu[WZ2dmO2aX;uJGF{e2G7	MXO1NE8yODBibl2=	NWW4NJNiOjRiaB?=	M2PHb2ROW09?	MoS3[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?=	M2fQeVI1ODl\|OUW2
HepG2	MnKxSpVv[3Srb36gRZN{[Xl?	NWnXOFZ3PTBxMUCwJI5O	NX3lW2dYOjRiaB?=	MUPEUXNQ	NYDjbFVZ\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=>	M3TINFI1ODl\|OUW2
SMMC-7721	M4HYW2Z2dmO2aX;uJGF{e2G7	MmjaOVAwOTByIH7N	MYmyOEBp	NX\WWVMzTE2VTx?=	NXruS41H\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=>	NXuxcFVbOjRyOUO5OVY>
HCC-LM3	MmnZSpVv[3Srb36gRZN{[Xl?	M3fRTlUxNzFyMDDuUS=>	NHPiUW4zPCCq	M4DiTWROW09?	M1O2fIRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25?	Ml7SNlQxQTN7NU[=
HepG2	NIXab3FHfW6ldHnvckBCe3OjeR?=	Mn;IOVAwOTByIH7N	MlflNlQhcA>?	NVjiO\|Z7TE2VTx?=	NXfj[JBZ\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?=	NW\0dXBCOjRyOUO5OVY>
SMMC-7721	M1jIUWZ2dmO2aX;uJGF{e2G7	MVG1NE8yODBibl2=	NInE[2wzPCCq	NVvTXIRHTE2VTx?=	MUHkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v	MkjrNlQxQTN7NU[=
FaDu	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3v4NlExOOLChX7N	MX[4M\|ExNzF{IHi=		NG\idHFlcXOybHH5[YQh[SC\|aXfubYZq[2GwdDDhcoQheHKxbH;u[4VlKEd{L12gZZJz\XO2IHH0JFgh[W6mIEGy5qCGcCCyb4P0JJJmdGWjc3W=	MWmyOFAzPjR6Mh?=
FaDu	MWrGeY5kfGmxbjDBd5NigQ>?	M3HBO\|ExOOLChX7N	MYWyM\|QwQC9zMjDo		M{PaOYlv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w	MmrXNlQxOjZ2OEK=
PC-3	NI\yc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXuwMVExKM7:TR?=	NUXCW2JUOjRxNEivO\|IhcA>?		M2rBPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NHrGOmkzOzl7MUKxOi=>
LNCaP	NIP6fJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVKwMVUh\|ryP	MlHkNlQwPDhxN{KgbC=>		NF35bFhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	Ml2xNlM6QTF{MU[=
RWPE-1	NXuyXVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\afFAuOjBizszN	NEfOU40zPC92OD:3NkBp		MmPsbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MkDoNlM6QTF{MU[=
Capan-1	NXLmOlZuTnWwY4Tpc44hSXO\|YYm=	NULrSJJbOjVxNUCvNVAxKG6P	NIHtcIg5NzJ2L{S4JIg>	M3;TV2ROW09?	M4DM[4Rwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW\|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne=	NUnldW1QOjN7MkK4PFY>
L3.6pl	NGPW[lNHfW6ldHnvckBCe3OjeR?=	NEHyeXIzPS93MD:xNFAhdk1?	MXO4M\|I1NzR6IHi=	MYPEUXNQ	M1zz[oRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW\|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne=	M2HVc\|I{QTJ{OEi2
CFPAC-1	NYnDVIRmTnWwY4Tpc44hSXO\|YYm=	NU\JWVlrOjVxNUCvNVAxKG6P	NG\SblM5NzJ2L{S4JIg>	Mny3SG1UVw>?	NYDMTWVP\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=>	NXnEPFlwOjN7MkK4PFY>
Capan-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXOyOU82OC9zMECgcm0>	NFfBZo81QCCq	M2PhNGROW09?	MU\y[YR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NH7nTpIzOzl{Mki4Oi=>
L3.6pl	MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYiyOU82OC9zMECgcm0>	NVfhVWh2PDhiaB?=	M4nmdmROW09?	M1HqepJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M1;ORVI{QTJ{OEi2
CFPAC-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTjWGwzPS93MD:xNFAhdk1?	M{\EOlQ5KGh?	MV3EUXNQ	NGjHfFVz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NH;GUVAzOzl{Mki4Oi=>
Capan-1	NVf3S2tNSXCxcITvd4l{KEG\|c3H5	M1nDSFI2NzVyL{GwNEBvVQ>?	NX;RSppRPDhiaB?=	NGOyR5BFVVOR	NHfJXHdqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NYLSUIROOjN7MkK4PFY>
L3.6pl	NX[xOJdISXCxcITvd4l{KEG\|c3H5	NXL1eY9yOjVxNUCvNVAxKG6P	MmrOOFghcA>?	NFfibGhFVVOR	NYn2TI1FcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NYf4WlJIOjN7MkK4PFY>
CFPAC-1	MnnFRZBweHSxc3nzJGF{e2G7	M4HqZlI2NzVyL{GwNEBvVQ>?	MlPYOFghcA>?	NVrMV\|NlTE2VTx?=	NHzoflJqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M2nFUVI{QTJ{OEi2
HN22	Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\nTFlYOC1{MDDuUS=>	M4rZZ\|I1NzR6IHi=	NFTxPIFFVVOR	MVTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy	M4TGR\|I{QDd5MkO1
HSC4	NWHDTWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUW2WFJLOC1{MDDuUS=>	M3HUbFI1NzR6IHi=	MnjjSG1UVw>?	M1nzZ4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI>	MkDQNlM5Pzd{M{W=
HN22	MnzXRZBweHSxc3nzJGF{e2G7	NEfpRpgxNTJyIH7N	M37BNFQ5KGh?	Mo[3SG1UVw>?	MlfXbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NFrmTXYzOzh5N{KzOS=>
HSC4	MW\BdI9xfG:\|aYOgRZN{[Xl?	NGTmbogxNTJyIH7N	NVfXOnlRPDhiaB?=	NIHo[5RFVVOR	MV7pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MkX4NlM5Pzd{M{W=
HN22	M4X5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX2wMVIxKG6P	MnXxOFghcA>?	NXq3fHNPTE2VTx?=	MX\pcoR2[2W\|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC=	M{LpTFI{QDd5MkO1
HSC4	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjWfWgxNTJyIH7N	MljDOFghcA>?	NVSweFlOTE2VTx?=	NYPtN\|BMcW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh	MormNlM5Pzd{M{W=
HN22	NUPBXnNlTnWwY4Tpc44hSXO\|YYm=	Mn[3NE0zOCCwTR?=	M3P5e\|Q5KGh?	MoHKSG1UVw>?	MojUd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg	NXLaOpRzOjN6N{eyN\|U>
HSC4	Mn\ESpVv[3Srb36gRZN{[Xl?	NEfYRlkxNTJyIH7N	MkjLOFghcA>?	NVTuN4c3TE2VTx?=	Mli2d5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg	M2m4RlI{QDd5MkO1
Cal62	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HuPGlEPTB;M{OgxtEhPCCwTR?=	MUeyN\|gzPDB4NB?=
Hth7	NIfEcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjSVGU2UUN3ME2xOUDDuSB{IH7N	NF36UW0zOzh{NEC2OC=>
Hth83	NXj2OndFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1G3bWlEPTB;M{SgxtEhPSCwTR?=	M2G1S\|I{QDJ2ME[0
C643	MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zVOGlEPTB;N{GgxtEhOTBibl2=	NXuzeZZjOjN6MkSwOlQ>
SW1736	NYrNZ4JKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzwXXBKSzVyPUO1JOKyKDhibl2=	Mn7HNlM5OjRyNkS=
T241	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{niNWlEPTB;NkWgxtEhPyCwTR?=	NWnhbnR7OjN6MkSwOlQ>
T351	NWHBeWtLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlP0TWM2OD13MDFCtUAyOCCwTR?=	NF;EWHAzOzh{NEC2OC=>
BHP2-7	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPZNmJbUUN3ME2zO{DDuSB4IH7N	M2\ae\|I{QDJ2ME[0
T238	NV:0XlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHMTWM2OD1zLEWwNEDDuSB{MECgcm0>	MnrtNlM5OjRyNkS=
HCT8	MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnGxO\|IhcA>?	Mk\ySG1UVw>?	M{XSXmlEPTB;MUKuPgKBkcLz4pEJNU46KG6P	MWiyN\|I6QTN6OB?=
H630	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3XuZlczKGh?	M3LEV2ROW09?	MWjJR\|UxRTF{LkVihKnDueLCiUOuNUBvVQ>?	M336b\|I{Ojl7M{i4
cH630 5-FU-res	MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEHaU3U4OiCq	Mn\lSG1UVw>?	M4rETWlEPTB;MUWuOgKBkcLz4pEJNU4zKG6P	NF7uZ2ozOzJ7OUO4PC=>
HCT116	MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGfkVoI4OiCq	MlT0SG1UVw>?	MoPJTWM2OD1zMD635qCKyrIkgJmyMlIhdk1?	Mmn4NlMzQTl\|OEi=
HCT116 p53−/−	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVm3NkBp	Ml3QSG1UVw>?	Moq1TWM2OD16LkdihKnDueLCiUGuO{BvVQ>?	MnjoNlMzQTl\|OEi=
dHCT116 p21−/−	M1TMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mk[2O\|IhcA>?	NUS0NIxpTE2VTx?=	NXnP[HV3UUN3ME21MlnjiIoEsfMAjVEvOyCwTR?=	Ml\qNlMzQTl\|OEi=
HT29	NFTheGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHX4bVI4OiCq	NFXBXG5FVVOR	MlzhTWM2OD1zNj6z5qCKyrIkgJmyMlMhdk1?	MUmyN\|I6QTN6OB?=
LoVo	NIjudIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUK3NkBp	NXXsR2g3TE2VTx?=	MV3JR\|UxRTVwMfMAjeKy6oDLMD62JI5O	NYnm[nRPOjN{OUmzPFg>
RKO	M4XXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlH2O\|IhcA>?	NFPn[FFFVVOR	M4PF[2lEPTB;Nz655qCKyrIkgJmyMlIhdk1?	NUX4R5BjOjN{OUmzPFg>
SW480	NEHWe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkToO\|IhcA>?	M2fSXWROW09?	NIeyfnFKSzVyPUG3MlXjiIoEsfMAjVAvQCCwTR?=	NHjOUmgzOzJ7OUO4PC=>
eSW620	NGG5U5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV[3NkBp	NWHqZ2xmTE2VTx?=	MVfJR\|UxRTlwMfMAjeKy6oDLMj6xJI5O	M4HhXlI{Ojl7M{i4

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

体内研究

LBH589作用于患肺癌和间皮瘤动物模型,明显降低肿瘤生长，与对照组相比平均降低62%。LBH589作用于免疫活性鼠和严重联合免疫缺陷鼠效果差不多，说明LBH589抑制肿瘤生长与免疫学无关。LBH589按20 mg/kg剂量腹腔注射，每周持续5天，导致在实验最后肿瘤生长平均下降70%。与相应的对照组肿瘤相比，LBH589作用于H526衍生的肿瘤下降53%，作用于BK-T衍生的肿瘤下降81%, 作用于RG-1衍生的肿瘤下降76%，作用于H69衍生的肿瘤下降 70%。在相同条件和剂量的情况下，LBH589 作用于NSCLC和Meso衍生的移植瘤，导致SCLC衍生的肿瘤中有两种衰退，伴随着BK-T衍生的平均肿瘤尺寸从实验开始时的296 mm³降低到实验结束时的116 mm³，RG-1衍生的平均肿瘤尺寸从实验开始时的185mm³降低到实验结束时的86 mm³。^[2]

细胞实验：^[1]	+ 展开 Cell lines: MOLT-4细胞和Reh(前体B细胞) Concentrations: 50 nM Incubation Time: 48小时 Method: 没有处理的细胞和LBH589处理的细胞[人类急性成淋巴细胞性白血病MOLT-4(T 细胞)和Reh(前体-B细胞)]用膜联蛋白V和碘化丙啶染色，然后加入膜联蛋白V-FITC细胞凋亡检测试剂盒I。通过流式细胞仪测定细胞凋亡和不能存活细胞的百分比。用CyAn ADP Violet细胞计数器收集至少5×10⁴个细胞。根据所有的膜联蛋白V-阳性和膜联蛋白V/PI-阳性细胞细胞计算凋亡百分比，根据所有的膜联蛋白V-阳性和PI-阳性及膜联蛋白V/PI-阳性细胞计算细胞活力丢失百分比。 (Only for Reference)
动物实验：^[2]	+ 展开 Animal Models: 携带10×10⁶个M30细胞或5×10⁶个A549细胞的SCID鼠 Formulation: 溶于水的5%葡萄糖 Dosages: 10 mg/kg, 20 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+48% PEG 300+2% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Panobinostat (LBH589) SDF

分子量	349.43
化学式	C₂₁H₂₃N₃O₂
CAS号	404950-80-7
储存条件	3 years -20°C powder
储存条件	2 years -80°C in solvent
别名	NVP-LBH589

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03632317	Withdrawn	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	October 2019	Phase 2
NCT03982134	Withdrawn	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	September 2019	Phase 1
NCT03515915	Recruiting	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	April 23 2018	--
NCT02717455	Recruiting	Glioma	Pediatric Brain Tumor Consortium	June 28 2016	Phase 1
NCT02471430	Recruiting	HIV Infection	Massachusetts General Hospital\|Novartis\|Genentech Inc.	May 2016	Phase 1\|Phase 2
NCT02057640	Active not recruiting	Multiple Myeloma\|Kahler Disease\|Plasma-Cell Myeloma\|Myelomatosis	Case Comprehensive Cancer Center	May 22 2014	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to reconstitute the compound for in vivo mice study?
回答：
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

选择性强的HDAC抑制剂

RGFP966 : HDAC3-selective, IC50=80 nM.
选择性强的HDAC抑制剂

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

Panobinostat (LBH589)

客户使用Selleck该产品发表文献122篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Panobinostat (LBH589) SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on )

技术支持

常见问题及建议解决方法

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品